Akero Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Akero Therapeutics is gedaald met een gemiddeld jaarlijks tempo van -24.9%, terwijl de winst van de sector Biotechs jaarlijks groeide met 7.7%.

Belangrijke informatie

-24.9%

Groei van de winst

8.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie	-14.6%
Inkomstengroei	n/a
Rendement op eigen vermogen	-32.1%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Akero Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:0K4 Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-237	38	232
30 Jun 24	-204	36	198
31 Mar 24	-179	33	171
31 Dec 23	-152	31	142
30 Sep 23	-120	30	107
30 Jun 23	-116	33	93
31 Mar 23	-112	31	87
31 Dec 22	-112	30	85
30 Sep 22	-121	28	95
30 Jun 22	-110	21	89
31 Mar 22	-112	20	92
31 Dec 21	-101	19	82
30 Sep 21	-98	18	80
30 Jun 21	-95	18	78
31 Mar 21	-82	16	67
31 Dec 20	-79	15	65
30 Sep 20	-65	14	52
30 Jun 20	-59	13	49
31 Mar 20	-50	11	42
31 Dec 19	-44	9	37
30 Sep 19	-90	7	26
30 Jun 19	-86	5	13
31 Mar 19	-87	3	16
31 Dec 18	-82	2	12
30 Sep 18	-22	1	11

Kwaliteitswinsten: 0K4 is momenteel verliesgevend.

Groeiende winstmarge: 0K4 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 0K4 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 24.9% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 0K4 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 0K4 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -18.2% ).

Rendement op eigen vermogen

Hoge ROE: 0K4 heeft een negatief Return on Equity ( -32.13% ), omdat het momenteel verliesgevend is.

Akero Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

New major risk - Revenue and earnings growth

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

Co-Founder recently sold €404k worth of stock

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New minor risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold €1.9m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

Independent Director recently sold €1.1m worth of stock

Independent Director recently sold €12m worth of stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

High number of new directors

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients

New 90-day high: €27.80

Akero Therapeutics, Inc. Initiates Phase 2B Harmony Study of Efruxifermin (Efx) for the Treatment of NASH

New 90-day high: €27.00

New 90-day high: €25.00

New 90-day low: €20.20

New 90-day low: €20.60

Akero Therapeutics, Inc. Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

New 90-day low: €23.80

Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients in Ongoing Balanced Study

Akero Therapeutics to Present Data from Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk at The Liver Meeting® 2020

New 90-day low: €26.20

Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $188.213976 million.

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Microcap Value Index

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden